Riassunto
L’ipertermia maligna (MH) è una miopatia “farmacogenetica” ereditata come predisposizione allo sviluppo di un grave stato di ipermetabolismo muscolare nel corso di anestesie generali effettuate con l’impiego di miorilassanti di tipo depolarizzante come la succinilcolina e/o con l’impiego di gas anestetici alogenati. Responsabile della reazione ipermetabolica è un’abnorme quantità di Ca++ che il reticolo sarcoplasmatico riversa nel citoplasma muscolare attraverso il recettore rianodinico [1]. Non è ancora del tutto chiaro se, e in che misura, l’aumentato rilascio sia preceduto o comunque favorito dall’ingresso di Ca++ extracellulare attraverso il sarcolemma o attraverso il cosiddetto recettore diidropiridinico (DHPR), che è un canale del Ca++ voltaggio-dipendente situato esclusivamente nel tubo T e funzionalmente associato al recettore rianodinico [1–3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Bibliografia
Rossi AN, Dirksen RT. Sarcoplasmic reticulum: the dynamic calcium governor of muscle. Muscle Nerve 2006; 33:715–731.
Deuster PA, Bockman EL, Biscardi H et al. Verapamil and zero Ca++ alter response of cat muscle to halothane and caffeine. J Appl Physiol 1986; 60:935–941.
Rock E, Kozak-Reis G. Effect of halothane on the Ca++ transport system of surface membranes isolated from normal and malignant hyperthermia pig skeletal muscle. Arch Biochem Biophys 1987; 256:703–707.
Strazis KP, Fox AW. Malignant Hyperthermia: a review of published cases. Anesth Analg 1993; 77:297–304.
Larach MG, Brandom BW, Allen GC et al. Cardiac arrest and deaths associated with malignant hyperthermia in North America from 1987 to 2006. Anesthesiology 2008; 108:603–611.
Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications. Physiol Rev 1999; 79:763–854.
Endo M. Calcium release from sarcoplasmic reticulum. Physiol Rev 1977; 57:71–108.
Green G. A fatal case of malignant hyperthermia complicated by generalized compartment syndrome and rhabdomyolysis. Acta Anaesth Scand 2003; 47:619–621.
Lane JE, Brooks AG, Logan MS et al. An unusual case of malignant hyperthermia during desflurane anesthesia in an african-american patient. Anesth Analg 2000; 91:1032–1034.
Bendixen D, Skovgaard LT, Ording H. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Acta Anaesth Scand 1997; 41:480–484.
Fiacchino F, Borroni V. L’anestesia nel paziente miopatico. Ed Anestesia e Rianimazione. Milano 1983.
Fiacchino F, Bricchi M, Balestrini MR et al. La rabdomiolisi anestesiologica nella distrofia muscolare. Minerva Anestesiologica 1984; 50:521–526.
Farrel PT. Anaesthesia-induced rhabdomyolysis causing cardiac arrest: case report and review of anaesthesia and dystrophinopathies. Anaesth Intens Care 1994; 22:597–601.
Larach MG et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994. 80:771–779.
Brandom BW, Broadman LM, Ozolek JA et al. Could this be malignant hyperthermia? Anesth Analg 2008; 106:1328.
Loke J, Mac Lennan DH. Malignant Hyperthermia and Central Core disease: disorders of Ca++ release channels. Am J Med 1998, 104:470–486.
Allen GC, Larach MG. The sensitivity and specificity of the caffeine-halothane contracture test. A report from the North American MH Registry. Anesthesiology 1998; 88: 579–588.
Ording H et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subiects. Acta Anaest Scand 1997; 41:955–966.
Iaizzo PA, Lehmann-Horn F. Anesthetic complications in muscle disorders. Anesthesiology 1995; 82:1093–1096.
Fiacchino F. Rhabdomyolysis and succinylcholine. Anesthesiology 1996; 84:480.
Islander G, Rydenfelt K, Ranklev E, Bodelsson M. Male preponderance of patients testing for malignant hyperthermia susceptibility. Acta Anaesth Scand. 2007; 51:614–620.
Berman MC. Role of preoperative management in the development of malignant hyperthermia. Lancet 1973; 2:743.
Vladitiu GD, Hogan K, Saponara I et al. Carnitine-palmitoyl-transferase deficiency in malignant hyperthermia. Muscle Nerve 1993; 16:485–491.
Zierz S, Schmitt U. Inhibition of carnitine-palmitoyl-transferase by malonyl-CoA in human muscle is influenced by anesthesia. Anesthesiology 1989; 70:733.
Fiacchino F, Consonni F, Dulcamara A et al. Suxamethonium in children. Br J Anaesth 1996; 76:883.
Familiari M. Meccanismo d’azione della ketamina a livello di membrana. Minerva Anestesiologica 1977; 43:435–448.
Noguchi I, Sankawa H, Andou M. The effect of ketamine or thiamylal on succinylcholine-induced myoglobinemia. Anest Analg 1995; 81:1015–1018.
Fiacchino F, Bricchi M, Gemma M et al. Valutazione pre e postoperatoria della creatinkinasi plasmatica in 142 bambini sottoposti “senza complicazioni” ad anestesia per biopsia muscolare. Minerva Anestesiologica 1989; 55:11–19.
Isaacs H, Badenhorst M. False-negative results with muscle caffeine-halothane contracture testing for malignant hyperthermia. Anesthesiology 1993; 79:5–9.
Laver DR, Lenz GKE, Lamb GD. Regulation of the calcium release channel from rabbit skeletal muscle by the nucleotides ATP, AMP, IMP and Adenosine. J Physiol 2001; 537:763–778.
Mathieu A, Bogosian AJ, Ryan JF et al. Recrudescence after survival of an episode of malignant hyperthermia. Anesthesiology 1979; 51:454.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Italia
About this chapter
Cite this chapter
Fiacchino, F. (2009). Ipertermia maligna. In: Terapia delle malattie neurologiche. Springer, Milano. https://doi.org/10.1007/978-88-470-1120-5_42
Download citation
DOI: https://doi.org/10.1007/978-88-470-1120-5_42
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1119-9
Online ISBN: 978-88-470-1120-5
eBook Packages: MedicineMedicine (R0)